Dataset Information


Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.

ABSTRACT: Rituximab plus intravenous bolus chemotherapy is a standard treatment for immunocompetent patients with B-cell non-Hodgkin lymphoma (NHL). Some studies have suggested that rituximab is associated with excessive toxicity in HIV-associated NHL, and that infusional chemotherapy may be more effective. We performed a randomized phase 2 trial of rituximab (375 mg/m(2)) given either concurrently before each infusional etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone (EPOCH) chemotherapy cycle or sequentially (weekly for 6 weeks) after completion of all chemotherapy in HIV-associated NHL. EPOCH consisted of a 96-hour intravenous infusion of etoposide, doxorubicin, and vincristine plus oral prednisone followed by intravenous bolus cyclophosphamide given every 21 days for 4 to 6 cycles. In the concurrent arm, 35 of 48 evaluable patients (73%; 95% confidence interval, 58%-85%) had a complete response. In the sequential arm, 29 of 53 evaluable patients (55%; 95% confidence interval, 41%-68%) had a complete response. The primary efficacy endpoint was met for the concurrent arm only. Toxicity was comparable in the 2 arms, although patients with a baseline CD4 count less than 50/microL had a high infectious death rate in the concurrent arm. We conclude that concurrent rituximab plus infusional EPOCH is an effective regimen for HIV-associated lymphoma.


PROVIDER: S-EPMC2858478 | BioStudies | 2010-01-01

REPOSITORIES: biostudies

Similar Datasets

2012-01-01 | S-EPMC3310940 | BioStudies
2013-01-01 | S-EPMC3821722 | BioStudies
2018-01-01 | S-EPMC6697160 | BioStudies
2015-01-01 | S-EPMC4418191 | BioStudies
2019-01-01 | S-EPMC6774813 | BioStudies
2021-01-01 | S-EPMC7927888 | BioStudies
2018-01-01 | S-EPMC6342507 | BioStudies
2015-01-01 | S-EPMC4380725 | BioStudies
1000-01-01 | S-EPMC3755934 | BioStudies
2018-01-01 | S-EPMC5962410 | BioStudies